Amneal patents expiration
1. Lyvispah patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654124 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(17 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity
Dosage: GRANULES;ORAL
LYVISPAH family patents
2. Tigecycline patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(8 years from now) | |
| US9855355 | AMNEAL | Method and device for plasma-treating hollow bodies |
Apr, 2033
(8 years from now) | |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TIGECYCLINE family patents
3. Zomig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | AMNEAL | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | AMNEAL | Indolyl compounds for treating migraine |
May, 2013
(10 years ago) | |
| US6750237 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
| US7220767 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
|
US7220767 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(2 years ago) | |
|
US6750237 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 12, 2018 |
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 16 September, 2013
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: SPRAY;NASAL
ZOMIG family patents